世界の新型コロナウイルス感染症用デキサメタゾン市場予測 2022年-2028年

【英語タイトル】Global Dexamethasone for COVID-19 Market Growth 2022-2028

LP Informationが出版した調査資料(LPI22SM18980)・商品コード:LPI22SM18980
・発行会社(調査会社):LP Information
・発行日:2022年9月
・ページ数:127
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥512,400見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥768,600見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,024,800見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
世界経済が回復するにつれて、2021年の新型コロナウイルス感染症用デキサメタゾンの成長は前年から大幅に変化します。LPインフォメーション社の最新の調査によると、世界の新型コロナウイルス感染症用デキサメタゾン市場規模は、2021年のxxxドルから2022年にはxxxドルに達し、2021年~2022年間にxxx%の変化が予想されます。2028年には世界の新型コロナウイルス感染症用デキサメタゾン市場規模がxxxドルまで成長し、分析期間中にxxx%のCAGRを記録すると予想されます。
アメリカの新型コロナウイルス感染症用デキサメタゾン市場は2021年にxxxドルの市場規模が見込まれ、分析期間中は約xxx%のCAGRで成長すると予測されます。中国は世界の新型コロナウイルス感染症用デキサメタゾン市場のxxx%のシェアを占め、2028年までにxxxドルに達すると展望されます。ヨーロッパの新型コロナウイルス感染症用デキサメタゾンの状況については、ドイツが2028年までにxxxドルに達し、分析期間にわたってCAGRがxxx%になると予測されます。アジア太平洋地域では、日本と韓国の成長率が、今後5年間でそれぞれxxx%とxxx%になると展望されます。

世界の主要な新型コロナウイルス感染症用デキサメタゾンプレーヤーとして、Pfizer、 Novartis、 Merck & Co.、 Sanofi Pharmaceuticals、 Baxter International、 Zydus Cadila、 Endo International、 Aspen Pharmacare Holdings、 Hikma Pharmaceuticals、 Cipla Limited、 Wockhardt Limited、 Xspire Pharmaceuticals、 Fera Pharmaceuticals、 Aché Laboratórios、 WraSer Pharmaceuticals、 Mylan、 Bound Tree Medical、 Santa Cruz Biotechなどをカバーしています。売上の面では、世界最大の2社が2021年に約xxx%市場シェアを占めています。

当レポートでは、製品タイプ、アプリケーション(用途)、主要メーカー、主要地域および国ごとの新型コロナウイルス感染症用デキサメタゾン市場の包括的な概要、市場シェア、および成長機会を掲載します。

タイプ別のセグメンテーション:2017年~2022年までの内訳データと2028年まで予測データ
純度97%、純度99%、その他

アプリケーション(用途)別のセグメンテーション:2017年~2022年までの内訳データと2028年まで予測データ
病院、診療所、その他

当レポートは次の地域と国の市場規模データを掲載します。
南北アメリカ(アメリカ、カナダ、メキシコ、ブラジル)
アジア太平洋(中国、日本、韓国、東南アジア、インド、オーストラリア)
ヨーロッパ(ドイツ、フランス、イギリス、イタリア、ロシア)
中東/アフリカ(エジプト、南アフリカ、イスラエル、トルコ、GCC諸国)

また、当レポートは市場の競争状況と主要メーカーの詳細な分析を掲載します。
Pfizer、 Novartis、 Merck & Co.、 Sanofi Pharmaceuticals、 Baxter International、 Zydus Cadila、 Endo International、 Aspen Pharmacare Holdings、 Hikma Pharmaceuticals、 Cipla Limited、 Wockhardt Limited、 Xspire Pharmaceuticals、 Fera Pharmaceuticals、 Aché Laboratórios、 WraSer Pharmaceuticals、 Mylan、 Bound Tree Medical、 Santa Cruz Biotech

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要:新型コロナウイルス感染症用デキサメタゾンの年間販売量2017-2028、地域別現状・将来分析
・新型コロナウイルス感染症用デキサメタゾンのタイプ別セグメント:純度97%、純度99%、その他
・新型コロナウイルス感染症用デキサメタゾンのタイプ別販売量:2017-2022年の販売量、売上、市場シェア、販売価格
・新型コロナウイルス感染症用デキサメタゾンの用途別セグメント:病院、診療所、その他
・新型コロナウイルス感染症用デキサメタゾンの用途別販売量:2017-2022年の販売量、売上、市場シェア、販売価格

企業別世界の新型コロナウイルス感染症用デキサメタゾン市場
・企業別のグローバル新型コロナウイルス感染症用デキサメタゾン市場データ:2020-2022年の年間販売量、市場シェア
・企業別の新型コロナウイルス感染症用デキサメタゾンの年間売上:2020-2022年の売上、市場シェア
・企業別の新型コロナウイルス感染症用デキサメタゾン販売価格
・主要企業の新型コロナウイルス感染症用デキサメタゾン生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

新型コロナウイルス感染症用デキサメタゾンの地域別レビュー
・地域別の新型コロナウイルス感染症用デキサメタゾン市場規模2017-2022:年間販売量、売上
・主要国別の新型コロナウイルス感染症用デキサメタゾン市場規模2017-2022:年間販売量、売上
・南北アメリカの新型コロナウイルス感染症用デキサメタゾン販売の成長
・アジア太平洋の新型コロナウイルス感染症用デキサメタゾン販売の成長
・ヨーロッパの新型コロナウイルス感染症用デキサメタゾン販売の成長
・中東・アフリカの新型コロナウイルス感染症用デキサメタゾン販売の成長

南北アメリカ市場
・南北アメリカの国別の新型コロナウイルス感染症用デキサメタゾン販売量、売上(2017-2022)
・南北アメリカの新型コロナウイルス感染症用デキサメタゾンの種類別販売量
・南北アメリカの新型コロナウイルス感染症用デキサメタゾンの用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の新型コロナウイルス感染症用デキサメタゾン販売量、売上(2017-2022)
・アジア太平洋の新型コロナウイルス感染症用デキサメタゾンの種類別販売量
・アジア太平洋の新型コロナウイルス感染症用デキサメタゾンの用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の新型コロナウイルス感染症用デキサメタゾン販売量、売上(2017-2022)
・ヨーロッパの新型コロナウイルス感染症用デキサメタゾンの種類別販売量
・ヨーロッパの新型コロナウイルス感染症用デキサメタゾンの用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の新型コロナウイルス感染症用デキサメタゾン販売量、売上(2017-2022)
・中東・アフリカの新型コロナウイルス感染症用デキサメタゾンの種類別販売量
・中東・アフリカの新型コロナウイルス感染症用デキサメタゾンの用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・新型コロナウイルス感染症用デキサメタゾンの製造コスト構造分析
・新型コロナウイルス感染症用デキサメタゾンの製造プロセス分析
・新型コロナウイルス感染症用デキサメタゾンの産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル:直接販売チャンネル、間接販売チャンネル
・新型コロナウイルス感染症用デキサメタゾンの主要なグローバル販売業者
・新型コロナウイルス感染症用デキサメタゾンの主要なグローバル顧客

地域別の新型コロナウイルス感染症用デキサメタゾン市場予測レビュー
・地域別の新型コロナウイルス感染症用デキサメタゾン市場規模予測(2023-2028)
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・新型コロナウイルス感染症用デキサメタゾンのタイプ別市場規模予測
・新型コロナウイルス感染症用デキサメタゾンの用途別市場規模予測

主要企業分析
Pfizer、 Novartis、 Merck & Co.、 Sanofi Pharmaceuticals、 Baxter International、 Zydus Cadila、 Endo International、 Aspen Pharmacare Holdings、 Hikma Pharmaceuticals、 Cipla Limited、 Wockhardt Limited、 Xspire Pharmaceuticals、 Fera Pharmaceuticals、 Aché Laboratórios、 WraSer Pharmaceuticals、 Mylan、 Bound Tree Medical、 Santa Cruz Biotech
・企業情報
・新型コロナウイルス感染症用デキサメタゾン製品
・新型コロナウイルス感染症用デキサメタゾン販売量、売上、価格、粗利益(2020-2022)
・主要ビジネス概要
・最新動向

調査結果および結論
❖ レポートの概要 ❖

As the global economy mends, the 2021 growth of Dexamethasone for COVID-19 will have significant change from previous year. According to our (LP Information) latest study, the global Dexamethasone for COVID-19 market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Dexamethasone for COVID-19 market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Dexamethasone for COVID-19 market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Dexamethasone for COVID-19 market, reaching US$ million by the year 2028. As for the Europe Dexamethasone for COVID-19 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Dexamethasone for COVID-19 players cover Pfizer, Novartis, Merck & Co., and Sanofi Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Dexamethasone for COVID-19 market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
97% Purity
99% Purity
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospitals
Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Pfizer
Novartis
Merck & Co.
Sanofi Pharmaceuticals
Baxter International
Zydus Cadila
Endo International
Aspen Pharmacare Holdings
Hikma Pharmaceuticals
Cipla Limited
Wockhardt Limited
Xspire Pharmaceuticals
Fera Pharmaceuticals
Aché Laboratórios
WraSer Pharmaceuticals
Mylan
Bound Tree Medical
Santa Cruz Biotechnology
KingYork
Lingrui Pharmaceutical
North China Pharmaceutical
Shanghai Shyndec Pharmaceutical
Pharscin Pharmaceutical
China Resources Sanjiu Pharmaceutical
Reyphon Pharmaceutical

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dexamethasone for COVID-19 Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Dexamethasone for COVID-19 by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Dexamethasone for COVID-19 by Country/Region, 2017, 2022 & 2028
2.2 Dexamethasone for COVID-19 Segment by Type
2.2.1 97% Purity
2.2.2 99% Purity
2.2.3 Others
2.3 Dexamethasone for COVID-19 Sales by Type
2.3.1 Global Dexamethasone for COVID-19 Sales Market Share by Type (2017-2022)
2.3.2 Global Dexamethasone for COVID-19 Revenue and Market Share by Type (2017-2022)
2.3.3 Global Dexamethasone for COVID-19 Sale Price by Type (2017-2022)
2.4 Dexamethasone for COVID-19 Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Dexamethasone for COVID-19 Sales by Application
2.5.1 Global Dexamethasone for COVID-19 Sale Market Share by Application (2017-2022)
2.5.2 Global Dexamethasone for COVID-19 Revenue and Market Share by Application (2017-2022)
2.5.3 Global Dexamethasone for COVID-19 Sale Price by Application (2017-2022)
3 Global Dexamethasone for COVID-19 by Company
3.1 Global Dexamethasone for COVID-19 Breakdown Data by Company
3.1.1 Global Dexamethasone for COVID-19 Annual Sales by Company (2020-2022)
3.1.2 Global Dexamethasone for COVID-19 Sales Market Share by Company (2020-2022)
3.2 Global Dexamethasone for COVID-19 Annual Revenue by Company (2020-2022)
3.2.1 Global Dexamethasone for COVID-19 Revenue by Company (2020-2022)
3.2.2 Global Dexamethasone for COVID-19 Revenue Market Share by Company (2020-2022)
3.3 Global Dexamethasone for COVID-19 Sale Price by Company
3.4 Key Manufacturers Dexamethasone for COVID-19 Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dexamethasone for COVID-19 Product Location Distribution
3.4.2 Players Dexamethasone for COVID-19 Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Dexamethasone for COVID-19 by Geographic Region
4.1 World Historic Dexamethasone for COVID-19 Market Size by Geographic Region (2017-2022)
4.1.1 Global Dexamethasone for COVID-19 Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Dexamethasone for COVID-19 Annual Revenue by Geographic Region
4.2 World Historic Dexamethasone for COVID-19 Market Size by Country/Region (2017-2022)
4.2.1 Global Dexamethasone for COVID-19 Annual Sales by Country/Region (2017-2022)
4.2.2 Global Dexamethasone for COVID-19 Annual Revenue by Country/Region
4.3 Americas Dexamethasone for COVID-19 Sales Growth
4.4 APAC Dexamethasone for COVID-19 Sales Growth
4.5 Europe Dexamethasone for COVID-19 Sales Growth
4.6 Middle East & Africa Dexamethasone for COVID-19 Sales Growth
5 Americas
5.1 Americas Dexamethasone for COVID-19 Sales by Country
5.1.1 Americas Dexamethasone for COVID-19 Sales by Country (2017-2022)
5.1.2 Americas Dexamethasone for COVID-19 Revenue by Country (2017-2022)
5.2 Americas Dexamethasone for COVID-19 Sales by Type
5.3 Americas Dexamethasone for COVID-19 Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dexamethasone for COVID-19 Sales by Region
6.1.1 APAC Dexamethasone for COVID-19 Sales by Region (2017-2022)
6.1.2 APAC Dexamethasone for COVID-19 Revenue by Region (2017-2022)
6.2 APAC Dexamethasone for COVID-19 Sales by Type
6.3 APAC Dexamethasone for COVID-19 Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Dexamethasone for COVID-19 by Country
7.1.1 Europe Dexamethasone for COVID-19 Sales by Country (2017-2022)
7.1.2 Europe Dexamethasone for COVID-19 Revenue by Country (2017-2022)
7.2 Europe Dexamethasone for COVID-19 Sales by Type
7.3 Europe Dexamethasone for COVID-19 Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dexamethasone for COVID-19 by Country
8.1.1 Middle East & Africa Dexamethasone for COVID-19 Sales by Country (2017-2022)
8.1.2 Middle East & Africa Dexamethasone for COVID-19 Revenue by Country (2017-2022)
8.2 Middle East & Africa Dexamethasone for COVID-19 Sales by Type
8.3 Middle East & Africa Dexamethasone for COVID-19 Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dexamethasone for COVID-19
10.3 Manufacturing Process Analysis of Dexamethasone for COVID-19
10.4 Industry Chain Structure of Dexamethasone for COVID-19
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dexamethasone for COVID-19 Distributors
11.3 Dexamethasone for COVID-19 Customer
12 World Forecast Review for Dexamethasone for COVID-19 by Geographic Region
12.1 Global Dexamethasone for COVID-19 Market Size Forecast by Region
12.1.1 Global Dexamethasone for COVID-19 Forecast by Region (2023-2028)
12.1.2 Global Dexamethasone for COVID-19 Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Dexamethasone for COVID-19 Forecast by Type
12.7 Global Dexamethasone for COVID-19 Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Dexamethasone for COVID-19 Product Offered
13.1.3 Pfizer Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Dexamethasone for COVID-19 Product Offered
13.2.3 Novartis Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck & Co.
13.3.1 Merck & Co. Company Information
13.3.2 Merck & Co. Dexamethasone for COVID-19 Product Offered
13.3.3 Merck & Co. Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Merck & Co. Main Business Overview
13.3.5 Merck & Co. Latest Developments
13.4 Sanofi Pharmaceuticals
13.4.1 Sanofi Pharmaceuticals Company Information
13.4.2 Sanofi Pharmaceuticals Dexamethasone for COVID-19 Product Offered
13.4.3 Sanofi Pharmaceuticals Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Pharmaceuticals Main Business Overview
13.4.5 Sanofi Pharmaceuticals Latest Developments
13.5 Baxter International
13.5.1 Baxter International Company Information
13.5.2 Baxter International Dexamethasone for COVID-19 Product Offered
13.5.3 Baxter International Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Baxter International Main Business Overview
13.5.5 Baxter International Latest Developments
13.6 Zydus Cadila
13.6.1 Zydus Cadila Company Information
13.6.2 Zydus Cadila Dexamethasone for COVID-19 Product Offered
13.6.3 Zydus Cadila Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Zydus Cadila Main Business Overview
13.6.5 Zydus Cadila Latest Developments
13.7 Endo International
13.7.1 Endo International Company Information
13.7.2 Endo International Dexamethasone for COVID-19 Product Offered
13.7.3 Endo International Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Endo International Main Business Overview
13.7.5 Endo International Latest Developments
13.8 Aspen Pharmacare Holdings
13.8.1 Aspen Pharmacare Holdings Company Information
13.8.2 Aspen Pharmacare Holdings Dexamethasone for COVID-19 Product Offered
13.8.3 Aspen Pharmacare Holdings Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Aspen Pharmacare Holdings Main Business Overview
13.8.5 Aspen Pharmacare Holdings Latest Developments
13.9 Hikma Pharmaceuticals
13.9.1 Hikma Pharmaceuticals Company Information
13.9.2 Hikma Pharmaceuticals Dexamethasone for COVID-19 Product Offered
13.9.3 Hikma Pharmaceuticals Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Hikma Pharmaceuticals Main Business Overview
13.9.5 Hikma Pharmaceuticals Latest Developments
13.10 Cipla Limited
13.10.1 Cipla Limited Company Information
13.10.2 Cipla Limited Dexamethasone for COVID-19 Product Offered
13.10.3 Cipla Limited Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Cipla Limited Main Business Overview
13.10.5 Cipla Limited Latest Developments
13.11 Wockhardt Limited
13.11.1 Wockhardt Limited Company Information
13.11.2 Wockhardt Limited Dexamethasone for COVID-19 Product Offered
13.11.3 Wockhardt Limited Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Wockhardt Limited Main Business Overview
13.11.5 Wockhardt Limited Latest Developments
13.12 Xspire Pharmaceuticals
13.12.1 Xspire Pharmaceuticals Company Information
13.12.2 Xspire Pharmaceuticals Dexamethasone for COVID-19 Product Offered
13.12.3 Xspire Pharmaceuticals Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Xspire Pharmaceuticals Main Business Overview
13.12.5 Xspire Pharmaceuticals Latest Developments
13.13 Fera Pharmaceuticals
13.13.1 Fera Pharmaceuticals Company Information
13.13.2 Fera Pharmaceuticals Dexamethasone for COVID-19 Product Offered
13.13.3 Fera Pharmaceuticals Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Fera Pharmaceuticals Main Business Overview
13.13.5 Fera Pharmaceuticals Latest Developments
13.14 Aché Laboratórios
13.14.1 Aché Laboratórios Company Information
13.14.2 Aché Laboratórios Dexamethasone for COVID-19 Product Offered
13.14.3 Aché Laboratórios Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Aché Laboratórios Main Business Overview
13.14.5 Aché Laboratórios Latest Developments
13.15 WraSer Pharmaceuticals
13.15.1 WraSer Pharmaceuticals Company Information
13.15.2 WraSer Pharmaceuticals Dexamethasone for COVID-19 Product Offered
13.15.3 WraSer Pharmaceuticals Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 WraSer Pharmaceuticals Main Business Overview
13.15.5 WraSer Pharmaceuticals Latest Developments
13.16 Mylan
13.16.1 Mylan Company Information
13.16.2 Mylan Dexamethasone for COVID-19 Product Offered
13.16.3 Mylan Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Mylan Main Business Overview
13.16.5 Mylan Latest Developments
13.17 Bound Tree Medical
13.17.1 Bound Tree Medical Company Information
13.17.2 Bound Tree Medical Dexamethasone for COVID-19 Product Offered
13.17.3 Bound Tree Medical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Bound Tree Medical Main Business Overview
13.17.5 Bound Tree Medical Latest Developments
13.18 Santa Cruz Biotechnology
13.18.1 Santa Cruz Biotechnology Company Information
13.18.2 Santa Cruz Biotechnology Dexamethasone for COVID-19 Product Offered
13.18.3 Santa Cruz Biotechnology Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.18.4 Santa Cruz Biotechnology Main Business Overview
13.18.5 Santa Cruz Biotechnology Latest Developments
13.19 KingYork
13.19.1 KingYork Company Information
13.19.2 KingYork Dexamethasone for COVID-19 Product Offered
13.19.3 KingYork Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.19.4 KingYork Main Business Overview
13.19.5 KingYork Latest Developments
13.20 Lingrui Pharmaceutical
13.20.1 Lingrui Pharmaceutical Company Information
13.20.2 Lingrui Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.20.3 Lingrui Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.20.4 Lingrui Pharmaceutical Main Business Overview
13.20.5 Lingrui Pharmaceutical Latest Developments
13.21 North China Pharmaceutical
13.21.1 North China Pharmaceutical Company Information
13.21.2 North China Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.21.3 North China Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.21.4 North China Pharmaceutical Main Business Overview
13.21.5 North China Pharmaceutical Latest Developments
13.22 Shanghai Shyndec Pharmaceutical
13.22.1 Shanghai Shyndec Pharmaceutical Company Information
13.22.2 Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.22.3 Shanghai Shyndec Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.22.4 Shanghai Shyndec Pharmaceutical Main Business Overview
13.22.5 Shanghai Shyndec Pharmaceutical Latest Developments
13.23 Pharscin Pharmaceutical
13.23.1 Pharscin Pharmaceutical Company Information
13.23.2 Pharscin Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.23.3 Pharscin Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.23.4 Pharscin Pharmaceutical Main Business Overview
13.23.5 Pharscin Pharmaceutical Latest Developments
13.24 China Resources Sanjiu Pharmaceutical
13.24.1 China Resources Sanjiu Pharmaceutical Company Information
13.24.2 China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.24.3 China Resources Sanjiu Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.24.4 China Resources Sanjiu Pharmaceutical Main Business Overview
13.24.5 China Resources Sanjiu Pharmaceutical Latest Developments
13.25 Reyphon Pharmaceutical
13.25.1 Reyphon Pharmaceutical Company Information
13.25.2 Reyphon Pharmaceutical Dexamethasone for COVID-19 Product Offered
13.25.3 Reyphon Pharmaceutical Dexamethasone for COVID-19 Sales, Revenue, Price and Gross Margin (2020-2022)
13.25.4 Reyphon Pharmaceutical Main Business Overview
13.25.5 Reyphon Pharmaceutical Latest Developments
14 Research Findings and Conclusion



★調査レポート[世界の新型コロナウイルス感染症用デキサメタゾン市場予測 2022年-2028年] (コード:LPI22SM18980)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の新型コロナウイルス感染症用デキサメタゾン市場予測 2022年-2028年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆